Abstract:Background. The optimal duration of antibiotic treatment must strike a delicate balance: it must be long enough to achieve desirable efficacy yet short enough to prevent the development of toxicities, adverse events, and mitigate other arduous aspects related to patient burden. Historically, the approach used to determine duration of antibiotic treatment has been inefficient, severely impacting the refinement of therapeutics for tuberculosis where treatment duration, and its complications, can be extensive. Meeting the WHO's End TB target of developing shorter, more tolerable TB therapeutics will require rigorously re-evaluating best practices in duration-ranging trial designs and statistical methodologies. Many of the challenges in duration-ranging have parallels and proposed solutions in the field of dose-ranging where the literature is substantially more established and where the traditions of qualitative, pairwise comparison studies have been replaced with model-based approaches. Such methods are more efficient and allow for interpolation between the doses observed. Research on efficient study designs and methods for duration-ranging, while similarly attempting to capture a monotonic response relationship, has only just accelerated in earnest over the last two decades. Methods. This work examines the utility of cutting-edge dose-finding methods (such as MCP-Mod) for duration-ranging of TB treatments. We compare the operating characteristics of the adapted model-based duration-ranging methodologies against standard qualitative methods for the purposes of estimating optimal duration and describing the duration-response relationship, using a simulation study motivated by a Multi-Arm Multi-Stage Response Over Continuous Intervention (MAMS-ROCI) clinical trial design. We explore three specific targets: 1) power to detect a duration-response relationship, 2) ability to accurately reproduce the duration-response curve, and 3) ability to estimate the optimal duration within an acceptable margin of error. Results. We find that model-based methods outperform standard qualitative comparisons on every target examined, particularly when the sample size is constrained to that of a typical Phase II trial. Conclusions. We conclude that the success of the next era in TB therapeutics duration evaluation trials, and antibiotics duration-ranging more broadly, will meaningfully rely on the ability to simultaneous pair innovative model-based statistical methods with re-imagined study designs such as MAMS-ROCI.

Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial

121. Improving Predictive Value of Phase 2a TB Drug Development Models Through PET/CT Imaging (nexgen EBA)

Tailored guidance to apply the Estimand framework to Trials within Cohorts (TwiCs) studies

A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials

Estimands in Hematologic Oncology Trials

Treatment Effect Quantification for Time-to-event Endpoints -- Estimands, Analysis Strategies, and beyond

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice

Application of the estimand framework for an emulated trial using reference based multiple imputation to investigate informative censoring

Applying the estimands framework to non-inferiority trials: guidance on choice of hypothetical estimands for non-adherence and comparison of estimation methods

Defining estimands using a mix of strategies to handle intercurrent events in clinical trials

Estimands in clinical trials of complex disease processes

Defining estimands in clinical trials: A unified procedure

A novel estimand to adjust for rescue treatment in clinical trials

Comparison of methods for identifying the optimal treatment duration in trials for antibiotics

A safety estimand for late phase clinical trials where the analysis period varies over the subjects

Application of estimand framework to the design and analysis of multi-regional clinical trials

Conditional and Unconditional Treatment Effects in Randomized Clinical Trials: Estimands, Estimation, and Interpretation

On the analysis of tuberculosis studies with intermittent missing sputum data

Implementation of tripartite estimands using adherence causal estimators under the causal inference framework

What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD

Estimand for non-inferiority influenza vaccine immunogenicity trials